Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalie A Bezman

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|April 11, 2013
Stage-specific regulation of natural killer cell homeostasis and response against viral infection by microRNA-155Carolyn L Zawislak, Aimee M Beaulieu, Gabriel B Loeb, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2006
Adhesion- and degranulation-promoting adapter protein is required for efficient thymocyte development and selectionJennifer N Wu, Shereen Gheith, Natalie A Bezman, et al.
Nature Immunology|August 21, 2012
Molecular definition of the identity and activation of natural killer cellsNatalie A Bezman, Charles C Kim, Joseph C Sun, et al.
Blood|December 24, 2009
Mislocalization of SLP-76 leads to aberrant inflammatory cytokine and autoantibody productionGregory F Sonnenberg, Paul R Mangan, Natalie A Bezman, et al.
Cancers|December 16, 2020
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive MalignanciesChristie P M Verkleij, Amy Jhatakia, Marloes E C Broekmans, et al.
Oncoimmunology|September 22, 2017
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanismsTatiana Pazina, Ashley M James, Alexander W MacFarlane, et al.
Cancers|January 13, 2021
Alterations of NK Cell Phenotype in the Disease Course of Multiple MyelomaTatiana Pazina, Alexander W MacFarlane, Luca Bernabei, et al.
Cancer Immunology Research|August 22, 2019
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple MyelomaTatiana Pazina, Ashley M James, Kimberly B Colby, et al.
Blood Advances|January 4, 2018
PD-1 blockade enhances elotuzumab efficacy in mouse tumor modelsNatalie A Bezman, Amy Jhatakia, Alper Y Kearney, et al.
Molecular Cancer Therapeutics|April 15, 2018
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of ElotuzumabAhmed T Kurdi, Siobhan V Glavey, Natalie A Bezman, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Proceedings of the National Academy of Sciences of the United States of America|April 11, 2013
Stage-specific regulation of natural killer cell homeostasis and response against viral infection by microRNA-155Carolyn L Zawislak, Aimee M Beaulieu, Gabriel B Loeb, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 20, 2006
Adhesion- and degranulation-promoting adapter protein is required for efficient thymocyte development and selectionJennifer N Wu, Shereen Gheith, Natalie A Bezman, et al.
Nature Immunology|August 21, 2012
Molecular definition of the identity and activation of natural killer cellsNatalie A Bezman, Charles C Kim, Joseph C Sun, et al.
Blood|December 24, 2009
Mislocalization of SLP-76 leads to aberrant inflammatory cytokine and autoantibody productionGregory F Sonnenberg, Paul R Mangan, Natalie A Bezman, et al.
Cancers|December 16, 2020
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive MalignanciesChristie P M Verkleij, Amy Jhatakia, Marloes E C Broekmans, et al.
Oncoimmunology|September 22, 2017
The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanismsTatiana Pazina, Ashley M James, Alexander W MacFarlane, et al.
Cancers|January 13, 2021
Alterations of NK Cell Phenotype in the Disease Course of Multiple MyelomaTatiana Pazina, Alexander W MacFarlane, Luca Bernabei, et al.
Cancer Immunology Research|August 22, 2019
Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple MyelomaTatiana Pazina, Ashley M James, Kimberly B Colby, et al.
Blood Advances|January 4, 2018
PD-1 blockade enhances elotuzumab efficacy in mouse tumor modelsNatalie A Bezman, Amy Jhatakia, Alper Y Kearney, et al.
Molecular Cancer Therapeutics|April 15, 2018
Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of ElotuzumabAhmed T Kurdi, Siobhan V Glavey, Natalie A Bezman, et al.
Pageof 3